Shearman & Sterling represented Cowen and Company, LLC, SVB Securities LLC and Evercore Group L.L.C., as representatives of the underwriters, in connection with Nkarta, Inc.’s follow-on public offering of 15.33 million shares of common stock, including the underwriters’ full exercise of their over-allotment option to purchase up to 2 million additional shares. The shares were offered at a price to the public of $15.00 per share, resulting in gross proceeds to Nkarta of approximately $230 million.

Nkarta, Inc., headquartered in South San Francisco, is a clinical stage biopharmaceutical company focused on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer.

The Shearman & Sterling team below included associate Eric Dunbar (New York-IP Transactional).

The Team